Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies
NS Kiran, C Yashaswini, R Maheshwari… - ACS Pharmacology & …, 2024 - ACS Publications
Precision medicine is transforming colorectal cancer treatment through the integration of
advanced technologies and biomarkers, enhancing personalized and effective disease …
advanced technologies and biomarkers, enhancing personalized and effective disease …
Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review
V Braicu, P Stelian, L Fulger, G Verdes, D Brebu… - Diseases, 2024 - mdpi.com
This systematic review critically evaluates the impact of systemic treatments on outcomes
and quality of life (QoL) in patients with RAS-positive stage IV colorectal cancer, with studies …
and quality of life (QoL) in patients with RAS-positive stage IV colorectal cancer, with studies …
A retrospective study of Trifluridine/Tipiracil with fruquintinib in patients with chemorefractory metastatic colorectal cancer
J Zou, Y Wang, J Xu, J Li, T Wang, Y Zhang… - Journal of Clinical …, 2023 - mdpi.com
Introduction: Trifluridine/tipiracil (TAS-102) and fruquintinib are novel antitumor agents for
patients with refractory metastatic colorectal cancer (mCRC). We conducted a retrospective …
patients with refractory metastatic colorectal cancer (mCRC). We conducted a retrospective …
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
C Anastasio, I Donisi, V Del Vecchio, A Colloca… - Cellular & Molecular …, 2024 - Springer
Background Sodium-glucose transporter 2 (SGLT2) inhibitors (iSGLT2) are approved
medications for type 2 diabetes. Recent studies indicate that iSGLT2 inhibit the growth of …
medications for type 2 diabetes. Recent studies indicate that iSGLT2 inhibit the growth of …
Evaluation of peripheral blood inflammation indexes as prognostic markers for colorectal cancer metastasis
X Shen, M Xiang, J Tang, G Xiong, K Zhang, T Xia… - Scientific Reports, 2024 - nature.com
The aim of this study was to evaluate the prognostic value of peripheral blood inflammation
indexes in patients with metastatic Colorectal Cancer (CRC) and to establish a predictive …
indexes in patients with metastatic Colorectal Cancer (CRC) and to establish a predictive …
Comprehensive analysis of mutational features of colorectal cancer and multiple primary cancers including colorectal component: Data from the Cancer Genome Atlas
NN Timoshkina, DY Gvaldin, M Eid, D Alset… - Human Gene, 2024 - Elsevier
Colorectal cancer (CRC) is the second in mortality among cancers with high incidence
worldwide. About 5% of patients had a previous oncopathology and 20% develop a second …
worldwide. About 5% of patients had a previous oncopathology and 20% develop a second …
Association between microsatellite instability status, clinicopathological features and mitochondrial DNA amplification in patients with colorectal cancer
J Lu, H Tan, T Guo, X Chen, Z Tong - Oncology Letters, 2024 - spandidos-publications.com
The relationship between BRAF‑V600E mutations, mitochondrial DNA amplification and
microsatellite instability‑high (MSI‑H) in colorectal cancer (CRC) has yet to be fully …
microsatellite instability‑high (MSI‑H) in colorectal cancer (CRC) has yet to be fully …
[PDF][PDF] Precision medicine and immunotherapy advances transforming colorectal cancer treatment
TA Addissouky, IET El Sayed, MMA Ali… - Journal of …, 2024 - researchgate.net
Background Colorectal cancer (CRC) remains one of the most prevalent cancers and
leading causes of cancer mortality worldwide. Global disease burden has risen in tandem …
leading causes of cancer mortality worldwide. Global disease burden has risen in tandem …
Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3D In Vitro Cultures
K Unrug-Bielawska, D Earnshaw… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: SN-38, an active metabolite of irinotecan, exhibits toxicity to all
proliferating cells, causing dose-limiting and potentially life-threatening side effects. Newly …
proliferating cells, causing dose-limiting and potentially life-threatening side effects. Newly …
2024 年V1/V2 版《 NCCN 直肠癌临床实践指南》 更新要点解读
曹沁涵， 卓肖， 夏雨菡， 车杨曦， 陈敏 - 中国全科医学, 2024 - chinagp.net
结直肠癌(CRC) 发病率位居中国癌症发病率第二位, 同时也是消化系统中常见的恶性肿瘤之一.
随着医学研究的深入和科技的进步, 其诊疗策略也在不断演化. 美国国家综合癌症网络(NCCN) …
随着医学研究的深入和科技的进步, 其诊疗策略也在不断演化. 美国国家综合癌症网络(NCCN) …